GFGerald A. Faich

Gerald A. Faich

*This is an algorithmically generated author record based on publicly available information.

Gerald A. Faich has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Alan B Whitehouse

    Alan B Whitehouse MD, Otolaryngologist, Augusta ENT, University Hospital, Augusta, GA; Assistant Clinical Professor, Medical College of Georgia, Augusta

    1 shared publication
  • Daniel C Haverstock

    Daniel C Haverstock MS, Deputy Director Statistics, Global Biometry, Bayer Pharmaceuticals Corporation

    1 shared publication
  • Deborah A Church

    Deborah A Church MD, Director, Medical Sciences, Anti-Infectives, Bayer Pharmaceuticals Corporation

    1 shared publication
  • Joel Morganroth

    Joel Morganroth MD, Clinical Professor of Medicine, School of Medicine, University of Pennsylvania, Philadelphia, PA; Chief Scientist, eResearch Technology, Inc., Philadelphia

    1 shared publication
  • Jugroop S Brar

    Jugroop S Brar MD, Staff Physician, Saratoga Emergency Physicians, Saratoga Springs, NY

    1 shared publication
  • Peter Arcuri

    Peter Arcuri DO, Family Practitioner, Philadelphia

    1 shared publication

Latest Publications

  • Clinical Experience with Moxifloxacin in Patients with Respiratory Tract Infections

    by Gerald A Faich, Joel Morganroth, Alan B Whitehouse, Jugroop S Brar, Peter Arcuri, Steven F Kowalsky, Daniel C Haverstock, Roger A Celesk, Deborah A Church

    BACKGROUND: Moxifloxacin is an advanced-generation fluoroquinolone used primarily for the treatment of respiratory tract infections. OBJECTIVE: To further investigate moxifloxacin's general and cardiac safety and evaluate its efficacy in the community practice setting in a large surveillance study. METHODS: A total of 18 409 outpatients with suspected bacterial episodes of acute sinusitis, acute exacerbation of chronic bronchitis, or community-acquired pneumonia of mild to moderate severity were enrolled at 3377 community practice sites. Patients with sinusitis or pneumonia received once-daily oral moxifloxacin 400 mg for 10 days; those with bronchitis received 5 days' treatment. At follow-up, within 48 hours after the end of treatment, adverse event information was collected. An external safety committee assessed possible cardiac-related events. Efficacy was also evaluated at follow-up via the degree of resolution of clinical signs and symptoms. RESULTS: Of 18 374 safety-valid patients, 17.7% experienced adverse events and 14.3% experienced drug-related adverse events. The most common drug-related adverse events were nausea (5.3%), diarrhea (2.2%), and dizziness (2.0%). There was no clinical evidence of increased risk of cardiac arrhythmias with moxifloxacin treatment. Of 17 137 patients included in the efficacy analysis, 92.9% overall experienced clinical cure or improvement (92.8% with sinusitis, 92.9% with bronchitis, 94.1% with pneumonia). CONCLUSIONS: Once-daily oral moxifloxacin 400 mg was shown to be safe and effective in this trial for the treatment of respiratory tract infections of suspected bacterial origin in the clinical practice setting.


  • Troglitazone (Rezulin) and hepatic injury

    by Gerald A. Faich, Richard H. Moseley

    Purpose: Analyze US rates of reported severe liver disease for the oral hypoglycemic agent troglitazone from March 1997 through February 2000 and the possible effects of publicity on reporting.Methods: The number of troglitazone reports with liver failure and or hospitalization with jaundice or hyperbilirubinemia, made to the FDA and/or Parke‐Davis are used as numerators. The denominators are numbers of patients and person‐time estimates of exposure. Additionally, the amount of publicity about troglitazone during its marketing is quantified.Results: Approximately 1.92 million patients were treated with troglitazone from March 1997 through the end of February 2000 resulting in 1.6 million person‐years of exposure. Reports of 83 cases of liver failure associated with troglitazone were received (1 in 23 000 patients or 1 in 20 000 person‐years). Of the 83 cases, only 49 (59%) were classified by a hepatologist to be ‘possibly’ or ‘probably’ attributed to troglitazone. For the first, second, and third years of marketing, rates of reported hepatic failure per 100 000 person years exposure to troglitazone were 8.3, 5.3, and 2.7 respectively. Rates of reported liver disease involving hospitalizations with mention of jaundice and hyperbilirubinemia per 100 000 person‐years were 16.0, 6.1, and 3.6 respectively for these years. During the 3‐year marketing history of troglitazone, there were 470 lay press and 158 medical literature articles with mentions of hepatotoxicity for the drug.Conclusions: Rates of reported severe liver disease declined substantially during the second and third years of marketing of troglitazone. The decline followed increasingly stringent requirements for liver function test monitoring and may have been due to improved patient selection and management as a result of the widely publicized association between troglitazone and hepatotoxicity. Copyright © 2001 John Wiley & Sons, Ltd.